DK171895B1 - Aprotininhomologe med andre aminosyrer i stilling 15 i stedet for lysin, fremgangsmåde til deres fremstilling samt mellemprodukter ved fremstillingen - Google Patents

Aprotininhomologe med andre aminosyrer i stilling 15 i stedet for lysin, fremgangsmåde til deres fremstilling samt mellemprodukter ved fremstillingen Download PDF

Info

Publication number: DK171895B1
Authority: DK; Denmark
Prior art keywords: aprotinin; lysine; ester; alanine; residue
Prior art date: 1983-07-28

Application number

DK369284A

Other languages

Danish (da)

English (en)

Other versions

DK369284A (da

DK369284D0 (da

Inventor

Harald Tschesche

Herbert Wenzel

Rainer Schmuck

Eugen Schnabel

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-07-28

Filing date

1984-07-27

Publication date

1997-08-04

1983-11-03 Priority claimed from DE19833339693 external-priority patent/DE3339693A1/de

1984-07-27 Application filed by Bayer Ag filed Critical Bayer Ag

1984-07-27 Publication of DK369284D0 publication Critical patent/DK369284D0/da

1985-01-29 Publication of DK369284A publication Critical patent/DK369284A/da

1997-08-04 Application granted granted Critical

1997-08-04 Publication of DK171895B1 publication Critical patent/DK171895B1/da

Links

229960004405 aprotinin Drugs 0.000 title claims description 148
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 title claims description 101
108010039627 Aprotinin Proteins 0.000 title claims description 97
150000001413 amino acids Chemical group 0.000 title claims description 29
238000000034 method Methods 0.000 title claims description 14
239000004472 Lysine Substances 0.000 title claims description 13
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 title claims description 13
238000002360 preparation method Methods 0.000 title claims description 10
230000008569 process Effects 0.000 title claims description 8
239000000543 intermediate Substances 0.000 title claims description 4
150000002148 esters Chemical class 0.000 claims description 89
229940024606 amino acid Drugs 0.000 claims description 33
235000001014 amino acid Nutrition 0.000 claims description 33
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 15
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 15
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 14
229960003767 alanine Drugs 0.000 claims description 14
150000001718 carbodiimides Chemical class 0.000 claims description 13
238000009833 condensation Methods 0.000 claims description 13
230000005494 condensation Effects 0.000 claims description 13
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 12
UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims description 10
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 10
-1 La-aminobutyric acid Chemical compound 0.000 claims description 8
235000004279 alanine Nutrition 0.000 claims description 8
229960004295 valine Drugs 0.000 claims description 8
239000004471 Glycine Substances 0.000 claims description 7
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 7
239000004395 L-leucine Substances 0.000 claims description 7
235000019454 L-leucine Nutrition 0.000 claims description 7
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 7
229960003136 leucine Drugs 0.000 claims description 7
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 6
SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 claims description 6
QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 6
FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 6
229930064664 L-arginine Natural products 0.000 claims description 6
235000014852 L-arginine Nutrition 0.000 claims description 6
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
229930195722 L-methionine Natural products 0.000 claims description 6
SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims description 6
125000004185 ester group Chemical group 0.000 claims description 6
229960004452 methionine Drugs 0.000 claims description 6
UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims description 5
UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical compound NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 claims description 5
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
229930182844 L-isoleucine Natural products 0.000 claims description 5
229960000310 isoleucine Drugs 0.000 claims description 5
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 4
229960002449 glycine Drugs 0.000 claims description 4
230000002378 acidificating effect Effects 0.000 claims description 3
229940124277 aminobutyric acid Drugs 0.000 claims description 3
150000001875 compounds Chemical class 0.000 claims description 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 3
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
235000018417 cysteine Nutrition 0.000 claims description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 2
125000005907 alkyl ester group Chemical group 0.000 claims 4
QWCKQJZIFLGMSD-VKHMYHEASA-N L-alpha-aminobutyric acid Chemical compound CC[C@H](N)C(O)=O QWCKQJZIFLGMSD-VKHMYHEASA-N 0.000 claims 2
210000004899 c-terminal region Anatomy 0.000 claims 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 claims 1
125000002843 carboxylic acid group Chemical group 0.000 claims 1
WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
239000000243 solution Substances 0.000 description 89
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 86
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 53
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
238000006243 chemical reaction Methods 0.000 description 42
239000000126 substance Substances 0.000 description 35
102000004190 Enzymes Human genes 0.000 description 33
108090000790 Enzymes Proteins 0.000 description 33
229940088598 enzyme Drugs 0.000 description 33
229960000583 acetic acid Drugs 0.000 description 30
239000000872 buffer Substances 0.000 description 25
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
239000003112 inhibitor Substances 0.000 description 21
239000000203 mixture Substances 0.000 description 21
108090000631 Trypsin Proteins 0.000 description 20
102000004142 Trypsin Human genes 0.000 description 20
239000012588 trypsin Substances 0.000 description 20
238000007792 addition Methods 0.000 description 19
230000005764 inhibitory process Effects 0.000 description 19
206010061218 Inflammation Diseases 0.000 description 15
230000015572 biosynthetic process Effects 0.000 description 15
230000004054 inflammatory process Effects 0.000 description 15
230000000694 effects Effects 0.000 description 14
239000000758 substrate Substances 0.000 description 14
238000003786 synthesis reaction Methods 0.000 description 13
108010028275 Leukocyte Elastase Proteins 0.000 description 12
102000016799 Leukocyte elastase Human genes 0.000 description 12
229920005654 Sephadex Polymers 0.000 description 12
239000012507 Sephadex™ Substances 0.000 description 12
239000011521 glass Substances 0.000 description 12
230000007062 hydrolysis Effects 0.000 description 12
238000006460 hydrolysis reaction Methods 0.000 description 12
239000003480 eluent Substances 0.000 description 11
238000004108 freeze drying Methods 0.000 description 11
238000004128 high performance liquid chromatography Methods 0.000 description 11
239000011780 sodium chloride Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
102000016387 Pancreatic elastase Human genes 0.000 description 10
108010067372 Pancreatic elastase Proteins 0.000 description 10
239000008363 phosphate buffer Substances 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
230000002255 enzymatic effect Effects 0.000 description 9
238000002523 gelfiltration Methods 0.000 description 9
238000000502 dialysis Methods 0.000 description 8
230000002401 inhibitory effect Effects 0.000 description 8
238000000108 ultra-filtration Methods 0.000 description 8
239000013543 active substance Substances 0.000 description 7
239000012141 concentrate Substances 0.000 description 7
238000001704 evaporation Methods 0.000 description 7
230000008020 evaporation Effects 0.000 description 7
238000001914 filtration Methods 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 6
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 6
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 6
108090000617 Cathepsin G Proteins 0.000 description 6
102000004173 Cathepsin G Human genes 0.000 description 6
108090000317 Chymotrypsin Proteins 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
102000035195 Peptidases Human genes 0.000 description 6
108091005804 Peptidases Proteins 0.000 description 6
239000007853 buffer solution Substances 0.000 description 6
229960002376 chymotrypsin Drugs 0.000 description 6
238000005886 esterification reaction Methods 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
210000003714 granulocyte Anatomy 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
230000014759 maintenance of location Effects 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
239000002904 solvent Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 5
102000005367 Carboxypeptidases Human genes 0.000 description 5
108010006303 Carboxypeptidases Proteins 0.000 description 5
229920002684 Sepharose Polymers 0.000 description 5
230000008033 biological extinction Effects 0.000 description 5
238000003776 cleavage reaction Methods 0.000 description 5
238000010612 desalination reaction Methods 0.000 description 5
230000032050 esterification Effects 0.000 description 5
WTDHULULXKLSOZ-UHFFFAOYSA-N hydroxylamine hydrochloride Substances Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 5
WCYJQVALWQMJGE-UHFFFAOYSA-M hydroxylammonium chloride Chemical compound [Cl-].O[NH3+] WCYJQVALWQMJGE-UHFFFAOYSA-M 0.000 description 5
230000000717 retained effect Effects 0.000 description 5
230000007017 scission Effects 0.000 description 5
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
102000003670 Carboxypeptidase B Human genes 0.000 description 4
108090000087 Carboxypeptidase B Proteins 0.000 description 4
102000029816 Collagenase Human genes 0.000 description 4
108060005980 Collagenase Proteins 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
150000007945 N-acyl ureas Chemical class 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
229960002424 collagenase Drugs 0.000 description 4
238000006911 enzymatic reaction Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000012362 glacial acetic acid Substances 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
238000004255 ion exchange chromatography Methods 0.000 description 4
229960005190 phenylalanine Drugs 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
235000019833 protease Nutrition 0.000 description 4
230000035484 reaction time Effects 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000000926 separation method Methods 0.000 description 4
238000001228 spectrum Methods 0.000 description 4
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 4
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
239000004475 Arginine Substances 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108060005987 Kallikrein Proteins 0.000 description 3
102000001399 Kallikrein Human genes 0.000 description 3
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
239000008351 acetate buffer Substances 0.000 description 3
239000002253 acid Substances 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
235000009697 arginine Nutrition 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
239000006227 byproduct Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000011049 filling Methods 0.000 description 3
ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 3
238000005194 fractionation Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
239000002808 molecular sieve Substances 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
229940012957 plasmin Drugs 0.000 description 3
238000011533 pre-incubation Methods 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000007974 sodium acetate buffer Substances 0.000 description 3
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
238000010254 subcutaneous injection Methods 0.000 description 3
239000008362 succinate buffer Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 2
229910002012 Aerosil® Inorganic materials 0.000 description 2
239000005995 Aluminium silicate Substances 0.000 description 2
201000001320 Atherosclerosis Diseases 0.000 description 2
101100289888 Caenorhabditis elegans lys-5 gene Proteins 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
206010014561 Emphysema Diseases 0.000 description 2
208000004232 Enteritis Diseases 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
206010033645 Pancreatitis Diseases 0.000 description 2
239000004365 Protease Substances 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
101000605527 Rattus norvegicus Kallikrein-1 Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
102000057032 Tissue Kallikreins Human genes 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
239000003463 adsorbent Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
235000012211 aluminium silicate Nutrition 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
239000012062 aqueous buffer Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000002532 enzyme inhibitor Substances 0.000 description 2
229940125532 enzyme inhibitor Drugs 0.000 description 2
210000002683 foot Anatomy 0.000 description 2
210000000548 hind-foot Anatomy 0.000 description 2
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
238000011534 incubation Methods 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
230000002601 intratumoral effect Effects 0.000 description 2
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
229940050906 magnesium chloride hexahydrate Drugs 0.000 description 2
DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 2
239000012528 membrane Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
150000004702 methyl esters Chemical class 0.000 description 2
239000011707 mineral Substances 0.000 description 2
230000035772 mutation Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
WYMSBXTXOHUIGT-UHFFFAOYSA-N paraoxon Chemical compound CCOP(=O)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 WYMSBXTXOHUIGT-UHFFFAOYSA-N 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
230000005855 radiation Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
239000012723 sample buffer Substances 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
230000008961 swelling Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
239000002753 trypsin inhibitor Substances 0.000 description 2
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
238000005303 weighing Methods 0.000 description 2
IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
MCHZKGNHFPNZDP-UHFFFAOYSA-N 2-aminoethane-1,1,1-triol;hydrochloride Chemical compound Cl.NCC(O)(O)O MCHZKGNHFPNZDP-UHFFFAOYSA-N 0.000 description 1
SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 1
SYSONWGWZNHPNT-UHFFFAOYSA-N 3-(cyclohexyliminomethylideneamino)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.CN(C)CCCN=C=NC1CCCCC1 SYSONWGWZNHPNT-UHFFFAOYSA-N 0.000 description 1
WSQMDYFCVVQJBJ-UHFFFAOYSA-N 3-(tert-butyliminomethylideneamino)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.CN(C)CCCN=C=NC(C)(C)C WSQMDYFCVVQJBJ-UHFFFAOYSA-N 0.000 description 1
DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
241000258957 Asteroidea Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
102000005572 Cathepsin A Human genes 0.000 description 1
108010059081 Cathepsin A Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000258742 Dermasterias imbricata Species 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
108010014173 Factor X Proteins 0.000 description 1
229940123583 Factor Xa inhibitor Drugs 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
208000035965 Postoperative Complications Diseases 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710119640 Trypsin-4 Proteins 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
XQYZOBNLCUAXLF-XRIGFGBMSA-N [(2s)-5-[[amino(azaniumyl)methylidene]amino]-1-methoxy-1-oxopentan-2-yl]azanium;dichloride Chemical compound Cl.Cl.COC(=O)[C@@H](N)CCCN=C(N)N XQYZOBNLCUAXLF-XRIGFGBMSA-N 0.000 description 1
238000003916 acid precipitation Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
239000012670 alkaline solution Substances 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000003024 amidolytic effect Effects 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001475 anti-trypsic effect Effects 0.000 description 1
229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000002849 elastaseinhibitory effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000010931 ester hydrolysis Methods 0.000 description 1
230000000058 esterolytic effect Effects 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
229940039088 kininogenase Drugs 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012160 loading buffer Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
229960002337 magnesium chloride Drugs 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
HTWQUGILRGGBDZ-UHFFFAOYSA-N methanol;thionyl dichloride Chemical compound OC.ClS(Cl)=O HTWQUGILRGGBDZ-UHFFFAOYSA-N 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
KUGLDBMQKZTXPW-JEDNCBNOSA-N methyl (2s)-2-amino-3-methylbutanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)C(C)C KUGLDBMQKZTXPW-JEDNCBNOSA-N 0.000 description 1
DODCBMODXGJOKD-RGMNGODLSA-N methyl (2s)-2-amino-4-methylpentanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC(C)C DODCBMODXGJOKD-RGMNGODLSA-N 0.000 description 1
YXMMTUJDQTVJEN-WDSKDSINSA-N methyl (2s,3s)-2-amino-3-methylpentanoate Chemical compound CC[C@H](C)[C@H](N)C(=O)OC YXMMTUJDQTVJEN-WDSKDSINSA-N 0.000 description 1
IODNYRVZHKRFIW-UHFFFAOYSA-N methyl 2-aminopentanoate;hydrochloride Chemical compound Cl.CCCC(N)C(=O)OC IODNYRVZHKRFIW-UHFFFAOYSA-N 0.000 description 1
230000004899 motility Effects 0.000 description 1
FHPQETVUIVUIQZ-UHFFFAOYSA-N n,n-dimethyl-3-(propan-2-yliminomethylideneamino)propan-1-amine;hydrochloride Chemical compound Cl.CC(C)N=C=NCCCN(C)C FHPQETVUIVUIQZ-UHFFFAOYSA-N 0.000 description 1
230000002956 necrotizing effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000008816 organ damage Effects 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
239000008057 potassium phosphate buffer Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000011282 treatment Methods 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
239000004474 valine Substances 0.000 description 1
238000003809 water extraction Methods 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
- C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Analytical Chemistry (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

DK369284A 1983-07-28 1984-07-27 Aprotininhomologe med andre aminosyrer i stilling 15 i stedet for lysin, fremgangsmåde til deres fremstilling samt mellemprodukter ved fremstillingen DK171895B1 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DE3327277		1983-07-28
DE3327277		1983-07-28
DE3339693		1983-11-03
DE19833339693 DE3339693A1 (de)	1983-11-03	1983-11-03	Homologe des aprotinin mit anderen aminosaeuren in position 15 anstelle von lysin, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel

Publications (3)

Publication Number	Publication Date
DK369284D0 DK369284D0 (da)	1984-07-27
DK369284A DK369284A (da)	1985-01-29
DK171895B1 true DK171895B1 (da)	1997-08-04

Family

ID=25812701

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK369284A DK171895B1 (da)	1983-07-28	1984-07-27	Aprotininhomologe med andre aminosyrer i stilling 15 i stedet for lysin, fremgangsmåde til deres fremstilling samt mellemprodukter ved fremstillingen
DK060993A DK171441B1 (da)	1983-07-28	1993-05-27	Lægemiddel indeholdende mindst en aprotininhomolog

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK060993A DK171441B1 (da)	1983-07-28	1993-05-27	Lægemiddel indeholdende mindst en aprotininhomolog

Country Status (14)

Country	Link
US (1)	US4595674A (cs)
EP (1)	EP0132732B1 (cs)
JP (1)	JPH0686479B2 (cs)
KR (1)	KR890004784B1 (cs)
AU (1)	AU560584B2 (cs)
CA (1)	CA1238000A (cs)
DE (1)	DE3471940D1 (cs)
DK (2)	DK171895B1 (cs)
ES (1)	ES8601858A1 (cs)
GR (1)	GR82265B (cs)
HU (1)	HU199880B (cs)
IE (1)	IE57628B1 (cs)
IL (1)	IL72494A (cs)
NZ (1)	NZ209001A (cs)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5871956A (en) *	1984-12-06	1999-02-16	Amgen Inc.	Recombinant methods for production of serine inhibitors and DNA sequences useful for same
US6291662B1 (en)	1984-12-05	2001-09-18	Amgen Inc.	Recombinant methods for production of serine protease inhibitors and DNA sequences
US6132990A (en) *	1984-12-06	2000-10-17	Amgen Boulder Inc.	Recombinant methods for production of serine protease inhibitors and DNA sequences useful for same
US5900400A (en) *	1984-12-06	1999-05-04	Amgen Inc.	Serine protease inhibitor analogs
DE3587526T3 (de) *	1984-12-06	2002-08-08	Amgen Inc.(N.D.Ges D. Staates Delaware), Thousand Oaks	Serinproteaseinhibitoren und isolierungsverfahren dazu.
FI854634A0 (fi) *	1985-11-22	1985-11-22	Labsystems Oy	Foerfarande foer bestaemning av proteolytisk aktivitet.
GB2188322A (en) *	1986-03-26	1987-09-30	Bayer Ag	Aprotinin and analogues thereof produced by a recombinant host
GB2188933A (en) *	1986-04-10	1987-10-14	Bayer Ag	Expression vectors for production of polypeptides, method for enhanced expression of polypeptides, hosts containing the expression vectors, products manufactured thereby
US5187153A (en) *	1986-11-17	1993-02-16	Scios Nova Inc.	Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US5223482A (en) *	1986-11-17	1993-06-29	Scios Nova Inc.	Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5220013A (en) *	1986-11-17	1993-06-15	Scios Nova Inc.	DNA sequence useful for the detection of Alzheimer's disease
GB2199582A (en) *	1987-01-07	1988-07-13	Bayer Ag	Analogues of pancreatic secretory trypsin inhibitor
US5032573A (en) *	1987-03-23	1991-07-16	Bayer Aktiengesellschaft	Homologs of aprotinin produced from a recombinant host, process, expression vector and recombinant host therefor and pharmaceutical use thereof
JP2656944B2 (ja) *	1987-04-30	1997-09-24	クーパーラボラトリーズ	タンパク質性治療剤のエアロゾール化
DE3724570A1 (de) *	1987-06-27	1989-01-05	Bayer Ag	Human-aprotinin, dessen lys-rest in position 15 gegen einen anderen protogenen aminosaeurerest ausgetauscht ist
GB2208511A (en) *	1987-08-07	1989-04-05	Bayer Ag	Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK225488D0 (da) *	1988-04-26	1988-04-26	Novo Industri As	Polypeptid
US5591603A (en) *	1987-08-28	1997-01-07	Novo Nordisk A/S	Process for preparing aprotinin and aprotinin analogs in yeast cells
US5223409A (en) *	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
WO1992015605A2 (en) *	1991-03-01	1992-09-17	Protein Engineering Corporation	Inhibitors of human neutrophil elastase and human cathepsin g
US20060134087A1 (en) *	1988-09-02	2006-06-22	Dyax Corp.	ITI-D1 Kunitz domain mutants as hNE inhibitors
US4994367A (en) *	1988-10-07	1991-02-19	East Carolina University	Extended shelf life platelet preparations and process for preparing the same
US5866413A (en) *	1989-03-06	1999-02-02	Board Of Regents Of The University Of Texas System	Pai-1 mutants
DK0462207T3 (da) *	1989-03-06	2001-06-18	Univ Texas	t-Pa mutanter resistente mod deres respektive inhibitorer
ES2066033T3 (es) *	1989-05-13	1995-03-01	Bayer Ag	Inhibidores de las proteinasas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
US7413537B2 (en) *	1989-09-01	2008-08-19	Dyax Corp.	Directed evolution of disulfide-bonded micro-proteins
WO1992006191A1 (en) *	1990-09-28	1992-04-16	Protein Engineering Corporation	Proteinaceous anti-dental plaque agents
DE69233769D1 (de) *	1991-03-01	2009-09-24	Dyax Corp	Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
JPH07509229A (ja) *	1992-07-13	1995-10-12	コルバス・インターナショナル、インコーポレイテッド	ウシ膵トリプシン阻害因子から誘導される因子Ｘａの阻害因子
US6869925B1 (en) *	1992-09-09	2005-03-22	Amgen Inc.	Inhibition of retrovirus infection
TW492975B (en) *	1993-07-26	2002-07-01	Novartis Ag	Tryptase inhibitor
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE529444T1 (de) *	1994-01-11	2011-11-15	Dyax Corp	Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US6017880A (en) *	1994-03-09	2000-01-25	Amgen Inc.	Inhibition of retrovirus infection
DE4417353A1 (de) *	1994-05-18	1996-01-25	Bayer Ag	Verfahren zur Herstellung von rekombinantem Aprotinin und rekombinanten Aprotinin Varianten mit der natürlichen N-terminlaen Sequenz
DE19629982A1 (de) *	1996-07-25	1998-01-29	Bayer Ag	Aprotinin-Varianten mit verbesserten Eigenschaften
GB0103765D0 (en) *	2001-02-15	2001-04-04	Affitech As	Assay
KR20040004562A (ko) *	2001-03-27	2004-01-13	어웨어, 인크.	수신기 투과성 ｑ-모드
AU2002358921A1 (en) *	2001-07-10	2003-04-28	Omnio Ab	Novel drug targets for arthritis
DK2311432T3 (en)	2002-06-07	2015-02-02	Dyax Corp	Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
TR201900937T4 (tr)	2002-08-28	2019-02-21	Dyax Corp	Organların ve dokuların muhafaza edilmesine yönelik yöntem.
JP2007524348A (ja) *	2003-01-07	2007-08-30	ダイアックス、コープ	クニッツドメインライブラリー
US6989369B2 (en) *	2003-02-07	2006-01-24	Dyax Corp.	Kunitz domain peptides
US7910550B2 (en) *	2004-04-16	2011-03-22	Stc.Unm	Human kunitz-type inhibitor with enhanced antifibrinolytic activity
US7432238B2 (en) *	2004-04-16	2008-10-07	Stc.Unm	Human Kunitz-type inhibitor with enhanced antifibrinolytic activity
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20090223893A1 (en) *	2005-12-01	2009-09-10	Gjerde Douglas T	Method and Device for Desalting an Analyte
US20060118491A1 (en) *	2004-12-03	2006-06-08	Gjerde Douglas T	Method and device for desalting an analyte
DK1976985T3 (da)	2005-12-29	2013-10-21	Univ California	Fremgangsmåder og præparater relateret til mutant Kunitz-domæne I af TFPI-2
WO2008110301A1 (de) *	2007-03-13	2008-09-18	Bayer Schering Pharma Aktiengesellschaft	Aprotinin-varianten mit verbesserten eigenschaften
US8637454B2 (en) *	2009-01-06	2014-01-28	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
ES2688093T3 (es)	2010-01-06	2018-10-30	Dyax Corp.	Proteínas de unión a calicreína plasmática
IL269565B2 (en)	2011-01-06	2024-06-01	Dyax Corp	Plasma kallikrein binding proteins
EP3122782A4 (en)	2014-03-27	2017-09-13	Dyax Corp.	Compositions and methods for treatment of diabetic macular edema
BR112018011622A2 (pt)	2015-12-11	2018-11-27	Dyax Corp	método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
CA3167336A1 (en)	2020-01-13	2021-07-22	Takeda Pharmaceutical Company Limited	Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

1984
- 1984-06-28 AU AU30001/84A patent/AU560584B2/en not_active Ceased
- 1984-07-14 EP EP84108293A patent/EP0132732B1/de not_active Expired
- 1984-07-14 DE DE8484108293T patent/DE3471940D1/de not_active Expired
- 1984-07-25 NZ NZ209001A patent/NZ209001A/xx unknown
- 1984-07-25 IL IL72494A patent/IL72494A/xx not_active IP Right Cessation
- 1984-07-26 CA CA000459735A patent/CA1238000A/en not_active Expired
- 1984-07-26 GR GR75431A patent/GR82265B/el unknown
- 1984-07-27 ES ES534659A patent/ES8601858A1/es not_active Expired
- 1984-07-27 KR KR1019840004467A patent/KR890004784B1/ko not_active Expired
- 1984-07-27 JP JP59155720A patent/JPH0686479B2/ja not_active Expired - Lifetime
- 1984-07-27 DK DK369284A patent/DK171895B1/da not_active IP Right Cessation
- 1984-07-27 HU HU842891A patent/HU199880B/hu not_active IP Right Cessation
- 1984-07-27 IE IE1954/84A patent/IE57628B1/en not_active IP Right Cessation
1985
- 1985-03-13 US US06/711,340 patent/US4595674A/en not_active Expired - Lifetime
1993
- 1993-05-27 DK DK060993A patent/DK171441B1/da not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES534659A0 (es)	1985-11-16
US4595674A (en)	1986-06-17
DK369284A (da)	1985-01-29
DE3471940D1 (en)	1988-07-14
EP0132732A2 (de)	1985-02-13
IL72494A (en)	1988-02-29
NZ209001A (en)	1989-02-24
DK60993D0 (da)	1993-05-27
HU199880B (en)	1990-03-28
IL72494A0 (en)	1984-11-30
CA1238000A (en)	1988-06-14
DK171441B1 (da)	1996-10-28
DK369284D0 (da)	1984-07-27
EP0132732B1 (de)	1988-06-08
EP0132732A3 (en)	1986-02-05
JPH0686479B2 (ja)	1994-11-02
AU560584B2 (en)	1987-04-09
KR890004784B1 (ko)	1989-11-27
ES8601858A1 (es)	1985-11-16
KR850001288A (ko)	1985-03-18
JPS6056999A (ja)	1985-04-02
HUT34515A (en)	1985-03-28
GR82265B (cs)	1984-12-13
IE841954L (en)	1985-01-28
DK60993A (da)	1993-05-27
AU3000184A (en)	1985-01-31
IE57628B1 (en)	1993-02-10

Legal Events

Date	Code	Title	Description
1997-08-04	B1	Patent granted (law 1993)
1999-05-03	PBP	Patent lapsed

Publication	Publication Date	Title
DK171441B1 (da)	1996-10-28	Lægemiddel indeholdende mindst en aprotininhomolog
US4760130A (en)	1988-07-26	Serine protease inhibitors and methods for isolation of same
US4713369A (en)	1987-12-15	Oligopeptidylargininol derivatives and their homologs, a process for their preparation, their use and agents containing them
Mallory et al.	1973	Human pancreatic enzymes. Characterization of anionic human trypsin
JPS6322027A (ja)	1988-01-29	セリンプロテア−ゼ阻害剤
Jering et al.	1976	Replacement of Lysine by Arginine, Phenylalanine and Tryptophan in the Reactive Site of the Bovine Trypsin‐Kallikrein Inhibitor (Kunitz) and Change of the Inhibitory Properties
Wingard et al.	1972	Myxobacter AL-1 protease II: specific peptide bond cleavage on the amino side of lysine
US4118481A (en)	1978-10-03	Deamino derivatives of the kallikrein-trypsin inhibitor
JPS59106446A (ja)	1984-06-20	酵素の検出および測定用色原体基質
EP0205555B2 (en)	2002-04-10	Serine protease inhibitors and methods for isolation of same
Mayer et al.	1994	Recombinant expression and properties of the Kunitz‐type protease‐inhibitor module from human type VI collagen α3 (VI) chain
US5900400A (en)	1999-05-04	Serine protease inhibitor analogs
KR100213662B1 (ko)	1999-08-02	엘라스타제 저해활성을 갖는 신규 펩티드 및 그의 제조방법
Beckmann et al.	1989	Semisynthesis of Arg15, Glu15, Met15, and Nle15-aprotinin involving enzymatic peptide bond resynthesis
Carmona et al.	1996	Inhibition of angiotensin converting enzyme and potentiation of bradykinin by retro-inverso analogues of short peptides and sequences related to angiotensin I and bradykinin
EP1406920B1 (fr)	2006-11-15	Nouveaux substrats chromogenes et leur utilisation pour le dosage de l'activite de carboxypeptidases
Norioka et al.	1994	Identification of three catalytic triad constituents and Asp-225 essential for function of lysine-specific serine protease, Achromobacter protease I.
HIRADO et al.	1984	Purification and characterization of a bovine colostrum low molecular weight cysteine proteinase inhibitor
Groeger et al.	1991	Enzymatic semisynthesis of aprotinin homologues mutated in P′ positions
JPH0952900A (ja)	1997-02-25	亜鉛エンドペプチダーゼ２４−１５阻害剤として使用可能な新規ペプチド誘導体
Tanabe et al.	1994	Isolation and characterization of Streptoverticillium anticoagulant (SAC), a novel protein inhibitor of blood coagulation produced by Streptoverticillium cinnamoneum subsp. cinnamoneum
JPH05208999A (ja)	1993-08-20	セリンプロテアーゼインヒビターおよびこれを含有する医薬組成物
Fritz et al.	1971	Proteinase inhibitors from dog submandibular glands—isolation, amino acid composition, inhibition spectrum
Abe et al.	1979	Isolation and activities of the trypsin-modified vicia angustifolia proteinase inhibitor lacking carboxyl-terminal hexapeptide
US7405280B2 (en)	2008-07-29	Chromogenic substances and use thereof for the determination of carboxypeptidase activities